Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease

Lancet

Volumn 351, Issue 9098, 1998, Pages 252-255

  Race, Elizabeth M ^a   Adelson Mitty, Jennifer ^a   Kriegel, Gila R ^a   Barlam, Tamar F ^a   Reimann, Keith A ^a   Letvin, Norman L ^a   Japour, Anthony J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LEUKOCYTOSIS; LYMPH NODE BIOPSY; LYMPHADENITIS; LYMPHOCYTE COUNT; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL;

EID: 0032562015     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)04352-3     Document Type: Article

References (30)

1. 1 Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313: 277-84.
2. 2 Pearl L, Taylor W. A structural model for the retroviral proteases. Nature 1987; 329: 351-54.
3. 3 Debouck C, Gorniak J, Strickler H, et al. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 1987; 84: 8903-06.
4. 4 Copeland T, Oroszlan S. Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene Anal Techn 1988; 5: 109-15.
5. 5 Hellen C, Kräusslich H, Wimmer E. Proteolytic processing of polyproteins in the replication of RNA viruses. Biochemistry 1989; 28: 9881-90.
6. 6 Rose J, Craik C. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors. Am J Respir Crit Care Med 1994; 150: S176-82.
7. 7 Kohl N, Emini E, Schleif W, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90.
8. 8 Peng C, Ho B, Chang T, Chang N. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and infectivity. J Virol 1989; 63: 2550-56.
9. 9 Tomasselli A, Hui J, Sawyer T, et al. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem 1990; 265: 14675-83.
10. 10 Collier A, Coombs R, Schoenfeld D, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine: AIDS Clinical Trials Group. N Engl J Med 1996; 334: 1011-17.
11. 11 Danner S, Carr A, Leonard J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
12. 12 Markowitz M, Saag M, Powderly W, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-39.
13. 13 Massari F, Staszewski S, Berry P, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs zidovudine alone in zidovudine-naive patients. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: Program Addendum 9, 1995.
14. 14 Stein D, Fish D, Chodakewitz J, et al. Follow-up data from an open-label phase 1 evaluation of the HIV protease inhibitor MK-639. In: 3rd Conference on Retroviruses and Opportunistic Infections 1996; Program and abstracts: 80.
15. 15 Massari F, Conant M, Mellors J, et al. A phase II, open label, randomised study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. In: 3rd Conference on Retroviruses and Opportunistic Infections 1996; Program and abstracts: 90.
16. 16 Steigbigel R, Berry P, Mellors J, et al. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK-639) at escalating dose. In: 3rd Conference on Retroviruses and Opportunistic Infections 1996; Program and abstracts: 80.
17. 17 Roederer M, Dubs J, Anderson M, et al. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95: 2061-66.
18. 18 Chaisson RE, Moore RD, Richman DD, et al. The Zidovudine study group: incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992; 146: 285-89.
19. 19 Flegg PJ, Laing RB, Lee C, et al. Disseminated disease due to Mycobacterium avium complex in AIDS. QJM 1995; 88: 617-26.
20. 20 Havlik JA, Horsburgh CR Jr, Metchock B, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992; 165: 577-80.
21. 21 Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-85.
22. 22 Jacomet C, Rolla V, Salauze B, et al. Mycobacteriosis and AIDS: a retrospective study of 58 cases. In: International Conference on AIDS 1993; 9: 328 (abstr PO-B07-1156).
23. 23 Cadeo GP, El Hamad I, Rossi S, et al. Mycobacterial infections in AIDS. In: International Conference on AIDS 1990; 6: 249 (abstr Th.B.511).
24. 24 Wallace JM, Hannah JB. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome: a clinicopathologic study. Chest 1988; 93: 926-32.
25. 25 Klatt EC, Jensen DF, Meyer PR. Pathology of Mycobacterium avium-intracellulare infection in acquired immunodeficiency syndrome. Hum Pathol 1987; 18: 709-14.
26. 26 Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-29.
27. 27 Lederman M, Connick E, Landay A, et al. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir) preliminary results of ACTG 315. In: 4th Conference on Retroviruses and Opportunistic Infections 1997; Program and abstracts: 208 (abstr LB13).
28. 28 Michelet C, Arvieux C, Aubert V, et al. Viral ocular involvement after initiation of antiprotease inhibitor therapy. In: 4th Conference on Retroviruses and Opportunistic Infections 1997; Program and abstracts: 122 (abstr 315).
29. 29 Jacobson MA, Kramer F, Pavan PR, Owens S, Pollard R, NIAID ACTG Protocol 266 Team. Failure of highly active antiretroviral therapy (HAART) to prevent CMV retinitis despite a marked CD4-count increase. In: 4th Conference on Retroviruses and Opportunistic Infections 1997; Program and abstracts: 129 (abstr 353).
30. 30 Gilquin J, Piketty C, Thomas V, et al. Acute CMV infection in AIDS patients receiving combination therapy including protease inhibitors. In: 4th Conference on Retroviruses and Opportunistic Infections 1997; Program and abstracts: 129 (abstr 354).